Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer Inc

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) have

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Could Seek COVID-19 Vaccine Emergency Approval For Children Under 5 This Week

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are likely to submit a request for an emergency use authorization to the U.S.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer and BioNTech launch clinical trial for Omicron-specific vaccine

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Evening Standard

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Pfizer and BioNTech Launch Trial of Omicron-Targeted COVID Vaccine

Pfizer Inc and BioNTech SE said on Tuesday they started a clinical trial to test a new version of their vaccine specifically designed to target the COVID-19 Omicron variant, which has eluded some of the protection provided by the original two-dose vaccine regimen. The companies plan to test the immune…

Asharq Al-Awsat

Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows

A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ:

inkl

Read news from The Economist, FT, and more,
with one subscription

Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant

Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant

Pfizer Inc (NYSE: PFE) yesterday

Canada Approves Pfizer's At-Home COVID-19 Antiviral Treatment, But Deliveries Delayed

Canada Approves Pfizer's At-Home COVID-19 Antiviral Treatment, But Deliveries Delayed

Health Canada approved Pfizer Inc's (NYSE: PFE) oral antiviral treatment for mild to moderate cases of COVID-19 in adults.

1 … 10 11 12 13

Organisations

AstraZeneca Plc

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play